KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Paylocity Holding (PCTY) Capital Expenditures (2016 - 2025)

Paylocity Holding has reported Capital Expenditures over the past 13 years, most recently at $3.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $3.4 million for Q4 2025, up 133.98% from a year ago — trailing twelve months through Dec 2025 was $14.9 million (down 76.17% YoY), and the annual figure for FY2025 was $13.1 million, down 78.47%.
  • Capital Expenditures for Q4 2025 was $3.4 million at Paylocity Holding, down from $3.8 million in the prior quarter.
  • Over the last five years, Capital Expenditures for PCTY hit a ceiling of $49.0 million in Q2 2024 and a floor of -$32.5 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $3.6 million (2025), compared with a mean of $6.7 million.
  • Peak annual rise in Capital Expenditures hit 743.59% in 2024, while the deepest fall reached 711.3% in 2024.
  • Paylocity Holding's Capital Expenditures stood at $7.4 million in 2021, then crashed by 144.17% to -$3.3 million in 2022, then soared by 149.21% to $1.6 million in 2023, then plummeted by 711.3% to -$9.9 million in 2024, then skyrocketed by 133.98% to $3.4 million in 2025.
  • The last three reported values for Capital Expenditures were $3.4 million (Q4 2025), $3.8 million (Q3 2025), and -$32.5 million (Q2 2025) per Business Quant data.